Literature DB >> 8285612

Uptake of azithromycin by human monocytes and enhanced intracellular antibacterial activity against Staphylococcus aureus.

A P Meyer1, C Bril-Bazuin, H Mattie, P J van den Broek.   

Abstract

The uptake of azithromycin by human monocytes and the intracellular antibacterial activity of azithromycin against Staphylococcus aureus were investigated. With an extracellular pH of 6.9, the maximum intracellular concentration of azithromycin in monocytes was about six times the extracellular concentration. The half-life for diffusion was 44 min. The results support the view that no active transport is involved in the intracellular accumulation of azithromycin. In cell-free medium, the maximum effect of azithromycin on S. aureus was bacteriostasis, which was achieved at a concentration of 5 mg/liter. In contrast, concentrations greater than 1.5 mg of azithromycin per liter were bactericidal for S. aureus ingested by monocytes. The difference in maximum growth inhibition on S. aureus for the two conditions was 0.1.68 h-1 (95% confidence interval, 0.128 to 0.208). The concentration of the drug that achieved 50% of the maximum effect was 0.434 mg/liter for both conditions. The enhancement of the effect on S. aureus ingested by monocytes suggests that the intracellular environment in human monocytes favors the antibacterial action of azithromycin. Enhancement of the antibacterial activity of azithromycin was not observed with granulocytes.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8285612      PMCID: PMC192385          DOI: 10.1128/AAC.37.11.2318

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  Mechanism of azithromycin uptake in human polymorphonuclear leucocytes.

Authors:  H Laufen; A Wildfeuer; P Lach
Journal:  Arzneimittelforschung       Date:  1990-06

2.  Mean cell volume of human blood leucocytes and resident and activated murine macrophages.

Authors:  P H Nibbering; T P Zomerdijk; A J Corsèl-Van Tilburg; R Van Furth
Journal:  J Immunol Methods       Date:  1990-05-08       Impact factor: 2.303

3.  Cloxacillin and nafcillin: serum binding and its relationship to antibacterial effect in mice.

Authors:  H Mattie; W R Goslings; E L Noach
Journal:  J Infect Dis       Date:  1973-08       Impact factor: 5.226

4.  Excretion of erythromycin and its enhanced activity in urine against gram-negative bacilli with alkalinization.

Authors:  L D Sabath; D A Gerstein; P B Loder; M Finland
Journal:  J Lab Clin Med       Date:  1968-12

5.  Intraphagocytic activity of erythromycin, roxithromycin and azithromycin.

Authors:  D Milatovic
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-01       Impact factor: 3.267

6.  In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection.

Authors:  R P Gladue; G M Bright; R E Isaacson; M F Newborg
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

7.  Adherence of lysostaphin to and penetration into human monocytes.

Authors:  P J van den Broek; L F Buys; R van Furth
Journal:  Scand J Immunol       Date:  1985-02       Impact factor: 3.487

8.  Requirement of extracellular complement and immunoglobulin for intracellular killing of micro-organisms by human monocytes.

Authors:  P C Leijh; M T van den Barselaar; T L van Zwet; M R Daha; R van Furth
Journal:  J Clin Invest       Date:  1979-04       Impact factor: 14.808

9.  On the mechanisms of association of the macrolide antibiotic erythromycin with isolated human polymorphonuclear leucocytes.

Authors:  M Raghoebar; E Lindeyer; W B Van den Berg; C A Van Ginneken
Journal:  Biochem Pharmacol       Date:  1988-09-01       Impact factor: 5.858

10.  The antibacterial activity of benzylpenicillin against Staphylococcus aureus ingested by granulocytes.

Authors:  P J van den Broek; L F Buys; B M Aleman
Journal:  J Antimicrob Chemother       Date:  1990-06       Impact factor: 5.790

View more
  14 in total

Review 1.  Interactions among strategies associated with bacterial infection: pathogenicity, epidemicity, and antibiotic resistance.

Authors:  José L Martínez; Fernando Baquero
Journal:  Clin Microbiol Rev       Date:  2002-10       Impact factor: 26.132

2.  A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo.

Authors:  Leandro C Cerchietti; Alexandru F Ghetu; Xiao Zhu; Gustavo F Da Silva; Shijun Zhong; Marilyn Matthews; Karen L Bunting; Jose M Polo; Christophe Farès; Cheryl H Arrowsmith; Shao Ning Yang; Monica Garcia; Andrew Coop; Alexander D Mackerell; Gilbert G Privé; Ari Melnick
Journal:  Cancer Cell       Date:  2010-04-13       Impact factor: 31.743

3.  The phagosomal environment protects virulent Mycobacterium avium from killing and destruction by clarithromycin.

Authors:  C Fréhel; C Offredo; C de Chastellier
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

4.  Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia. The Azithromycin Intravenous Clinical Trials Group.

Authors:  J Plouffe; D B Schwartz; A Kolokathis; B W Sherman; P M Arnow; J A Gezon; B Suh; A Anzuetto; R N Greenberg; M Niederman; J A Paladino; J A Ramirez; J Inverso; C A Knirsch
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

5.  Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses.

Authors:  K M Olsen; G San Pedro; L P Gann; P O Gubbins; D M Halinski; G D Campbell
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

6.  New pharmacokinetic in vitro model for studies of antibiotic activity against intracellular microorganisms.

Authors:  K Hultén; R Rigo; I Gustafsson; L Engstrand
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

Review 7.  Ketolides--the modern relatives of macrolides : the pharmacokinetic perspective.

Authors:  Markus Zeitlinger; Claudia Christina Wagner; Birgit Heinisch
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

8.  Azithromycin in combination with riboflavin decreases the severity of Staphylococcus aureus infection induced septic arthritis by modulating the production of free radicals and endogenous cytokines.

Authors:  Pinky Mal; Kallol Dutta; Debasish Bandyopadhyay; Anirban Basu; Rajni Khan; Biswadev Bishayi
Journal:  Inflamm Res       Date:  2012-11-15       Impact factor: 4.575

9.  Intracellular activity of azithromycin against bacterial enteric pathogens.

Authors:  R M Rakita; K Jacques-Palaz; B E Murray
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

10.  Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages.

Authors:  Cristina Seral; Françoise Van Bambeke; Paul M Tulkens
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.